About Us

Overview

BetaStem is dedicated to utilizing the power of regenerative medicine to cure diabetic retinopathy, the leading cause of adult blindness in industrialized nations, which affects nearly 4 million people in the United States. There is no therapy that will cure diabetic retinopathy.

**Translating Advances in Regenerative Medicine**

Research at BetaStem has focused on advances in personalized medicine, particularly autologous stem cell therapy. BetaStem will rehabilitate the stem cells taken from each patient utilizing our proprietary technology. Once the patient’s stem cells are renewed, those cells will be returned to that patient’s diseased eye, beginning the process of a cure for diabetic retinopathy.

**Autologous Stem Cell Therapy**

Autologous stem cells are harvested from one patient with a common blood draw and re-delivered to that patient only. Autologous stem cell therapy has been approved for years. BetaStem is using technology to separate, treat, and return the rehabilitated cells to each patient in a very short time frame.

**The Advantage of Autologous Therapy**

Utilizing stem cells from one patient for that patient only allows BetaStem to avoid the risk of immune response to the therapy. Since the stem cells are from that patient, we avoid the serious risks of graft-versus-host disease.

Core Values

**Our Vision**

BetaStem’s vision is to bring the first curative therapy to patients suffering vision loss from diabetic retinopathy.

**BetaStem Values**

Focus on the Vision of the Patient

Integrity in the Pursuit of Science

Scientific Innovations and Established Protocols

Our Team will Develop the Cure Together

Leadership Team

Founder and Management

Stephen Bartelmez, PhD, Founder, President and CEO

Bio(expandable)

Charles A Garcia, MD, Practicing Surgical Ophthalmologist, CMO

Bio(expandable)

Robert Martinsons, Vice President, Marketing and Business Development

Bio(expandable)

Leland Johnson, MS, Director of Business Development and Corporate Strategy

Scientific Advisory Board

Board of Directors

Patrick Iversen, PhD (Sarepta)

Maria Grant, MD (Indiana University, formerly University of Florida)

Others

Therapeutic Approach

Diabetic Retinopathy

CD 34+ Platform

Diabetic Retinopathy Program

Media Center

News

Press releases

Scientific Publications

Patents

Publications

Careers

All positions filled at this time

Terms of Use

Do you have a standard template for terms of use?

Site Map

Standard Outline

Contact

Ideas:

Golden gate bridge original image / golden gate bridge with diabetic retinopathy

If you need higher-res images email lee

Logo design – similar to <http://www.thirdrockventures.com/portfolio.php>

Cmo – Charlie Garcia (Houston, TX)